SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Cancer is a leading cause of death in type 2 diabetes mellitus patients.
• Glucagon-like peptide-1 receptor agonists have shown promise against certain cancers.
• The anti-cancer potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors in breast cancer requires further investigation.

Purpose of the Study:

• To investigate the anti-cancer effects of the SGLT2 inhibitor ipragliflozin on a human breast cancer cell line (MCF-7).
• To elucidate the mechanism of action of ipragliflozin in breast cancer cells, focusing on SGLT2 inhibition.

Main Methods:

• Detection of SGLT2 expression in MCF-7 cells using RT-PCR and immunohistochemistry.
• Assessment of ipragliflozin's effect on cell growth and proliferation using cell counting and BrdU assays.
• Evaluation of ipragliflozin's impact on membrane potential and mitochondrial membrane potential using patch clamp techniques and JC-1 staining.
• Validation of SGLT2's role through SGLT2 gene knockdown using siRNA.

Main Results:

• SGLT2 was detected in MCF-7 human breast cancer cells.
• Ipragliflozin significantly and dose-dependently suppressed MCF-7 cell growth and proliferation.
• The anti-cancer effects of ipragliflozin were dependent on SGLT2 expression, as confirmed by gene knockdown experiments.
• Ipragliflozin induced membrane hyperpolarization and altered mitochondrial membrane potential in breast cancer cells, suggesting inhibition of sodium-glucose cotransport via SGLT2.

Conclusions:

• The SGLT2 inhibitor ipragliflozin demonstrates significant anti-cancer activity against breast cancer cells.
• Ipragliflozin's mechanism involves the inhibition of SGLT2, leading to membrane hyperpolarization and mitochondrial membrane instability.
• These findings suggest a potential therapeutic role for SGLT2 inhibitors in managing breast cancer, particularly in patients with type 2 diabetes.